| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$567,301 ) |
| | 2025 | 2022 | NORTIS INC | 17280 WOODINVILLE REDMOND RD NE | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES032393 | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | 000 | 3 | NIH | 10/23/2024 | -$567,301 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | NORTIS INC | 17280 WOODINVILLE REDMOND RD NE | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES035556 | A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds | 000 | 1 | NIH | 6/18/2024 | $0 |
| | 2024 | 2021 | NORTIS INC | 17280 WOODINVILLE REDMOND RD NE | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 3 | NIH | 5/20/2024 | $0 |
| | 2024 | 2020 | NORTIS INC | 17280 WOODINVILLE REDMOND RD NE | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 001 | 2 | NIH | 8/22/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $275,453 ) |
| | 2023 | 2023 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES035556 | A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds | 000 | 1 | NIH | 7/17/2023 | $275,453 |
| | 2023 | 2021 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 001 | 3 | NIH | 6/26/2023 | $0 |
| | 2023 | 2020 | NORTIS INC | 17280 WOODINVILLE REDMOND RD NE | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 002 | 2 | NIH | 8/11/2023 | $0 |
| | 2023 | 2020 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 2 | NIH | 12/21/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $803,596 ) |
| | 2022 | 2022 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES032393 | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | 001 | 3 | NIH | 4/28/2022 | $803,596 |
| | 2022 | 2020 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES032393 | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | 000 | 1 | NIH | 4/21/2022 | $0 |
| | 2022 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R43AG066020 | Organ-on-chip based assays for personalized assessment of renal resilience in aging patients | 000 | 1 | NIH | 2/24/2022 | $0 |
| | 2022 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 1 | NIH | 6/28/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,900,878 ) |
| | 2021 | 2021 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES032393 | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | 000 | 2 | NIH | 5/14/2021 | $876,058 |
| | 2021 | 2021 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 3 | NIH | 6/16/2021 | $1,024,820 |
|
| Issue Date FY: 2020 ( Subtotal = $1,532,665 ) |
| | 2020 | 2020 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44ES032393 | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | 000 | 1 | NIH | 8/20/2020 | $252,114 |
| | 2020 | 2020 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 002 | 2 | NIH | 8/11/2020 | $255,716 |
| | 2020 | 2020 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 001 | 2 | NIH | 7/3/2020 | $1,024,842 |
| | 2020 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R43AG066020 | Organ-on-chip based assays for personalized assessment of renal resilience in aging patients | 000 | 1 | NIH | 11/18/2019 | $0 |
| | 2020 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 1 | NIH | 7/2/2020 | $0 |
| | 2020 | 2017 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44NS095585 | A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | 000 | 3 | NIH | 3/30/2020 | -$7 |
|
| Issue Date FY: 2019 ( Subtotal = $631,413 ) |
| | 2019 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R43AG066020 | Organ-on-chip based assays for personalized assessment of renal resilience in aging patients | 000 | 1 | NIH | 9/16/2019 | $300,000 |
| | 2019 | 2019 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44TR003065 | Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | 000 | 1 | NIH | 8/21/2019 | $331,413 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2016 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R41TR001203 | A microfluidic quality-control assay for stem-cell derived therapies | 000 | 1 | NIH | 1/16/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $687,731 ) |
| | 2017 | 2017 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44NS095585 | A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | 001 | 3 | NIH | 8/15/2017 | $687,731 |
| | 2017 | 2015 | NORTIS, INC. | 17280 WOODINVILLE-REDMOND RD NE STE B-828 | WOODINVILLE | WA | 98072-9088 | KING | USA | R44NS095585 | A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | 000 | 1 | NIH | 11/30/2016 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,065,895 ) |
| | 2016 | 2016 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R44NS095585 | A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | 000 | 2 | NIH | 9/21/2016 | $700,895 |
| | 2016 | 2016 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R41TR001203 | A microfluidic quality-control assay for stem-cell derived therapies | 000 | 1 | NIH | 3/21/2016 | $325,000 |
| | 2016 | 2016 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R41TR001203 | A microfluidic quality-control assay for stem-cell derived therapies | 001 | 1 | NIH | 5/3/2016 | $40,000 |
|
| Issue Date FY: 2015 ( Subtotal = $964,884 ) |
| | 2015 | 2015 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R44HL107040 | Development of an Advanced In-Vitro Model for Angiogenesis Research and Drug Test | 000 | 4 | NIH | 4/29/2015 | $739,884 |
| | 2015 | 2015 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R44NS095585 | A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | 000 | 1 | NIH | 9/19/2015 | $225,000 |
|
| Issue Date FY: 2014 ( Subtotal = $770,090 ) |
| | 2014 | 2014 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R44HL107040 | Development of an Advanced In-Vitro Model for Angiogenesis Research and Drug Test | 000 | 3 | NIH | 7/25/2014 | $770,090 |
|
| Issue Date FY: 2012 ( Subtotal = $66,642 ) |
| | 2012 | 2011 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R43HL107040 | DEVELOPMENT OF AN ADVANCED IN-VITRO MODEL FOR ANGIOGENESIS RESEARCH AND DRUG TEST | 001 | 2 | NIH | 1/30/2012 | $42,507 |
| | 2012 | 2010 | NORTIS INC | 4000 MASON ROAD | SEATTLE | WA | 98195 | KING | USA | R43CA144469 | DEVELOPMENT OF A VASCULARIZED IN-VITRO MODEL OF THE TUMOR MICROENVIRONMENT | 001 | 2 | NIH | 5/9/2012 | $24,135 |
|
|
